Q-omics provides the consensus-scored C19orf71 profile across patient tissues and cancer cell-line models. C19orf71 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C19orf71 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, C19orf71 RNA expression shows 19,564 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, COAD, and ACC as cancer lineages where C19orf71 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C19orf71 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C19orf71 survival associations across molecular data types. C19orf71 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C19orf71 RNA expression–survival associations across cancer types. High C19orf71 expression shows unfavorable associations in MESO and ACC, but favorable associations in HNSC, PAAD, BLCA and STAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for C19orf71 RNA expression.
This table summarizes C19orf71 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C19orf71. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C19orf71 shows lower tumor expression in THCA and KIRP and higher tumor expression in COAD, HNSC, LIHC and STAD. The COAD box plot shows higher C19orf71 RNA expression in tumor versus normal tissue (log2 FC = +1.725, t-test p < 0.001).
This table shows molecular features associated with C19orf71 in patient tissues and cancer cell lines. In patient samples, C19orf71 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C19orf71 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
